Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5201
iShares ESG Advanced MSCI EAFE ETF
DMXF
$1.01B
| $805K | ﹤0.01% |
9,516
+429
| +5% | +$35.1K |
2021 Q4
18 quarters
|
|
5202
GeoPark
GPRK
$748M
| $804K | ﹤0.01% |
88,333
-60,305
| -41% | -$587K |
2016 Q4
38 quarters
|
|
5203
Pacific Biosciences
PACB
$609M
| $803K | ﹤0.01% |
477,776
-1,362,685
| -74% | -$1.98M |
2013 Q2
52 quarters
|
|
5204
Agenus
AGEN
$302M
| $802K | ﹤0.01% |
262,068
-33,753
| -11% | -$121K |
2013 Q2
52 quarters
|
|
5205
aTyr Pharma
ATYR
$18M
| $802K | ﹤0.01% |
1,343,636
+118,169
| +10% | +$77.2K |
2023 Q1
13 quarters
|
|
5206
Nuveen Minnesota Quality Municipal Income Fund
NMS
$64.6M
| $802K | ﹤0.01% |
66,197
+2,500
| +4% | +$30.5K |
2014 Q4
46 quarters
|
|
5207
ProShares UltraPro Short QQQ
SQQQ
$2.28B
| $801K | ﹤0.01% |
22,048
+14,521
| +193% | +$701K |
2018 Q2
32 quarters
|
|
5208
Akebia Therapeutics
AKBA
$193M
| $800K | ﹤0.01% |
701,540
+120,213
| +21% | +$143K |
2014 Q2
48 quarters
|
|
5209
Peerless Option Income Wheel ETF
WEEL
$47.6M
| $797K | ﹤0.01% |
+40,152
| New | +$812K |
2026 Q2
0 quarters
|
|
5210
Eightco Holdings
ORBS
$330M
| $797K | ﹤0.01% |
1,146,107
+19,229
| +2% | +$17.3K |
2022 Q2
16 quarters
|
|
5211
InnovAge Holding
INNV
$1.23B
| $796K | ﹤0.01% |
67,174
+44,100
| +191% | +$361K |
2021 Q1
21 quarters
|
|
5212
FT Energy Income Partners Strategy ETF
EIPX
$568M
| $795K | ﹤0.01% |
25,405
+205
| +0.8% | +$6.55K |
2023 Q4
10 quarters
|
|
5213
Crawford & Co Class A
CRD.A
$591M
| $793K | ﹤0.01% |
70,321
+2,622
| +4% | +$27.9K |
2013 Q2
52 quarters
|
|
5214
Virtus Biotech Clinical Trials ETF
BBC
$39.1M
| $792K | ﹤0.01% |
15,026
-210
| -1% | -$9.37K |
2015 Q1
45 quarters
|
|
5215
Sagimet Biosciences
SGMT
$579M
| $790K | ﹤0.01% |
102,227
+8,920
| +10% | +$60.7K |
2023 Q3
11 quarters
|
|
5216
John Marshall Bancorp
JMSB
$322M
| $790K | ﹤0.01% |
36,244
+14,945
| +70% | +$317K |
2022 Q2
16 quarters
|
|
5217
Lightbridge
LTBR
$189M
| $790K | ﹤0.01% |
89,863
-99,965
| -53% | -$1.13M |
2013 Q4
50 quarters
|
|
5218
Outset Medical
OM
$76.7M
| $786K | ﹤0.01% |
181,983
+12,540
| +7% | +$54.9K |
2020 Q3
23 quarters
|
|
5219
Forum Markets
FRMM
$49.8M
| $785K | ﹤0.01% |
144,535
-7,108
| -5% | -$31.1K |
2025 Q3
3 quarters
|
|
5220
Invesco Global ex-US High Yield Corporate Bond ETF
PGHY
$227M
| $782K | ﹤0.01% |
39,676
-335
| -0.8% | -$6.63K |
2013 Q4
50 quarters
|
|
5221
Huckleberry.ai, Inc. Class B Common Stock
HUCK
$151M
| $781K | ﹤0.01% |
249,425
-465,675
| -65% | -$1.56M |
2018 Q2
32 quarters
|
|
5222
iShares MSCI BIC ETF
BKF
$67.4M
| $770K | ﹤0.01% |
19,868
-1,448
| -7% | -$59.5K |
2013 Q2
52 quarters
|
|
5223
Fidelity Small-Mid Multifactor ETF
FSMD
$2.53B
| $769K | ﹤0.01% |
14,548
+10,280
| +241% | +$508K |
2022 Q3
15 quarters
|
|
5224
Global X Autonomous & Electric Vehicles ETF
DRIV
$339M
| $768K | ﹤0.01% |
19,920
+4,551
| +30% | +$172K |
2020 Q3
23 quarters
|
|
5225
American Coastal Insurance
ACIC
$518M
| $768K | ﹤0.01% |
69,183
-47,383
| -41% | -$523K |
2013 Q2
52 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.